REXULTI
As listed in the register: REXULTI
3 mg · tablet
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Brexpiprazole
- Made by
- Otsuka Pharmaceutical Co Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Brexpiprazole). It describes the substance, not this exact product.
The mechanism of action of brexpiprazole in the treatment of major depressive disorder or schizophrenia is unknown.
However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT 1A and dopamine D 2 receptors, and antagonist activity at serotonin 5-HT 2A receptors.
Based on in vitro metabolism studies of brexpiprazole using recombinant human cytochrome P450 (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4), the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6.
Less than 1% of unchanged brexpiprazole was excreted in the urine, and approximately 14% of the oral dose was recovered unchanged in the feces.
Brexpiprazole tablets can be administered with or without food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2022-12-13
Safety of the active substance
From the US prescribing label for the same active substance (Brexpiprazole). It describes the substance, not this exact product.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- Brexpiprazole tablets are contraindicated in patients with a known hypersensitivity to brexpiprazole or any of its components.
- Reactions have included rash, facial swelling, urticaria, and anaphylaxis.
- Known hypersensitivity to brexpiprazole tablets or any of its components ( 4 )
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States2 matching products
European UnionNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Otsuka Pharmaceutical Co Ltd |
|---|---|
| Active substance | Brexpiprazole |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 3 mg |
| Form | tablet |
| Classification | N05AX16 · Pain, sleep, mood, epilepsy and the brain |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02461781 |
| DPD drug code | 94954 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
6 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.